Brentuximab Vedotin Yields Modest Response in Relapsed Diffuse Large B-Cell Lymphoma
A systematic review indicates brentuximab vedotin regimens achieve modest responses in relapsed or refractory diffuse large B-cell lymphoma alongside substantial ...


